Evidence map›Paper›PMID 41403425›Full record

ArticleERJ open research2025

Short-acting β

John R Hurst, Dave Singh, Fernando J Martinez, Klaus F Rabe, Patrick Darken, Niki Arya, Charlotta Movitz, Karin Bowen, Mehul Patel

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02465567 (A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02465567 phase3completednot on this map

A Randomized, Double-Blind, Multi-Center, Parallel-Group Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 on COPD Exacerbations Over a 52-Week Treatment Period in Subjects With Moderate to Very Severe COPD (Ethos)

TypeinterventionalSponsorPearl Therapeutics, Inc.Ran2015 to 2019Enrolled8,588ConditionsCOPDArmsBGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BGF MDI 160/14.4/9.6 μg, BFF MDI 320/9.6 μg
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

John R HurstUCL Respiratory, University College London, London, UK.ORCID https://orcid.org/0000-0002-7246-6040
Dave SinghMedicines Evaluation Unit, University of Manchester, Manchester University NHS Foundation Hospitals Trust, Manchester, UK.
Fernando J MartinezDivision of Pulmonary, Allergy, and Critical Care Medicine, University of Massachusetts Chan, Worcester, MA, USA.
Klaus F RabeLungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, German Center for Lung Research (DZL), Grosshansdorf, Germany.
Patrick DarkenLate Respiratory and Immunology, Biometrics, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Niki AryaLate Respiratory and Immunology, Biometrics, Biopharmaceuticals R&D, AstraZeneca, Durham, NC, USA.
Charlotta MovitzLate Respiratory and Immunology, Biometrics, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Karin BowenLate Respiratory and Immunology, Biometrics, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.
Mehul PatelLate Respiratory and Immunology, Clinical Development, Biopharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Short-acting β Methods: In ETHOS (NCT02465567), symptomatic people with COPD and an exacerbation history were randomly assigned 1:1:1:1 to budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) (320/14.4/10 or 160/14.4/10 μg), glycopyrronium/formoterol fumarate dihydrate (GFF) (14.4/10 μg) or budesonide/formoterol fumarate dihydrate (BFF) (320/10 μg). Results: Across treatments, higher moderate/severe exacerbation rates were observed for participants with higher (range: 1.62-2.51) Conclusion: These results suggest increased SABA use is associated with an impending exacerbation. Further, BGF reduces exacerbation rates regardless of SABA use, with greater benefit in those with higher SABA use.

Identifiers

PMID41403425
PMCPMC12704147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.